| Subject: | FDA Issues Public Health Advisory About Adderall XR |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 24 Feb 2005 - 10:00 am |
| The FDA has issued a Public Health Advisory notifying healthcare providers about the suspended sale of Adderall XR (mixed salts of a single entity amphetamine product) by Canada's drug regulatory agency, Health Canada. The sale of Adderall XR (XR being the controlled release form of the medication) was suspended in Canada. Adderall is used in the treatment of ADHD. In the United States, Adderall XR is approved for the treatment of adults and pediatric patients (six to twelve years) with ADHD,... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|
